| 1.16 -0.02 (-1.69%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.55 | 1-year : | 1.77 |
| Resists | First : | 1.33 | Second : | 1.51 |
| Pivot price | 1.22 |
|||
| Supports | First : | 1.02 | Second : | 0.85 |
| MAs | MA(5) : | 1.11 |
MA(20) : | 1.26 |
| MA(100) : | 1.72 |
MA(250) : | 3.86 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 22.9 |
D(3) : | 13 |
| RSI | RSI(14): 38.9 |
|||
| 52-week | High : | 9.32 | Low : | 1.02 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ZYXI ] has closed above bottom band by 36.0%. Bollinger Bands are 14.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.19 - 1.2 | 1.2 - 1.21 |
| Low: | 1.08 - 1.09 | 1.09 - 1.1 |
| Close: | 1.15 - 1.16 | 1.16 - 1.17 |
Zynex, Inc., through its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography triggered electrical stimulation device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; and E-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and knee braces for knee support. Further, it offers Zynex Fluid Monitoring System (CM-1500), a fluid volume monitor, which is a non-invasive medical device for monitoring relative fluid volume changes used in operating and recovery rooms to detect fluid loss during surgery and internal bleeding during recovery; Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
Sun, 09 Nov 2025
Bronstein, Gewirtz & Grossman, LLC Encourages Zynex, Inc. (ZYXI) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Fri, 07 Nov 2025
Investors Don't See Light At End Of Zynex, Inc.'s (NASDAQ:ZYXI) Tunnel And Push Stock Down 28% - simplywall.st
Sat, 01 Nov 2025
Zynex CCO Resigns Amid Separation Negotiations - The Globe and Mail
Sat, 01 Nov 2025
Is Zynex (NASDAQ:ZYXI) A Risky Investment? - simplywall.st
Tue, 14 Oct 2025
Zynex Announces Appointment of Bret Wise to Board of Directors as Audit Committee Chair - PR Newswire
Thu, 14 Aug 2025
Zynex, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Distribution
|
|
| Shares Out | 30 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 48.3 (%) |
| Held by Institutions | 18.2 (%) |
| Shares Short | 3,440 (K) |
| Shares Short P.Month | 3,520 (K) |
| EPS | -0.94 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.03 |
| Profit Margin | -19.8 % |
| Operating Margin | -46.2 % |
| Return on Assets (ttm) | -12.2 % |
| Return on Equity (ttm) | -168.3 % |
| Qtrly Rev. Growth | -55.3 % |
| Gross Profit (p.s.) | 3.61 |
| Sales Per Share | 4.77 |
| EBITDA (p.s.) | -0.51 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | 4 (M) |
| PE Ratio | -1.25 |
| PEG Ratio | 0 |
| Price to Book value | 29 |
| Price to Sales | 0.24 |
| Price to Cash Flow | -4.9 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 8.6% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|